These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12003184)

  • 1. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in renal cell cancer.
    Skubitz KM
    Invest New Drugs; 2002 Feb; 20(1):101-4. PubMed ID: 12003184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma.
    Skubitz KM
    Cancer Invest; 2002; 20(5-6):693-9. PubMed ID: 12197225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma.
    Skubitz KM
    Cancer Invest; 2003 Apr; 21(2):167-76. PubMed ID: 12743981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
    Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing NI; Lotem M; Brufman G; Gabizon A
    Cancer; 2000 Sep; 89(5):1037-47. PubMed ID: 10964334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
    Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
    Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
    Pavlick AC; Chodkiewicz C; Liebes L; Hamilton A; Wasserheit C; Hochster H; Speyer J; Phillips Z; Downey A; Sorich J; Muggia F
    Anticancer Drugs; 2004 Feb; 15(2):119-25. PubMed ID: 15075667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
    Muggia FM; Hainsworth JD; Jeffers S; Miller P; Groshen S; Tan M; Roman L; Uziely B; Muderspach L; Garcia A; Burnett A; Greco FA; Morrow CP; Paradiso LJ; Liang LJ
    J Clin Oncol; 1997 Mar; 15(3):987-93. PubMed ID: 9060537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas.
    Chidiac T; Budd GT; Pelley R; Sandstrom K; McLain D; Elson P; Crownover R; Marks K; Muschler G; Joyce M; Zehr R; Bukowski R
    Invest New Drugs; 2000 Aug; 18(3):253-9. PubMed ID: 10958594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer.
    Hubert A; Lyass O; Pode D; Gabizon A
    Anticancer Drugs; 2000 Feb; 11(2):123-7. PubMed ID: 10789595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma.
    Law TM; Mencel P; Motzer RJ
    Invest New Drugs; 1994; 12(4):323-5. PubMed ID: 7775134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors.
    El-Rayes BF; Ibrahim D; Shields AF; LoRusso PM; Zalupski MM; Philip PA
    Invest New Drugs; 2005 Jan; 23(1):57-62. PubMed ID: 15528981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.
    Rocca A; Cecconetto L; Passardi A; Melegari E; Andreis D; Monti M; Maltoni R; Sarti S; Pietri E; Schirone A; Fabbri F; Donati C; Nanni O; Fedeli A; Faedi M; Amadori D
    Cancer Chemother Pharmacol; 2017 May; 79(5):863-871. PubMed ID: 28341957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.
    Ellerhorst JA; Bedikian A; Ring S; Buzaid AC; Eton O; Legha SS
    Oncol Rep; 1999; 6(5):1097-9. PubMed ID: 10425308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
    Gabizon A; Shmeeda H; Barenholz Y
    Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
    Rose PG
    Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
    Gabizon AA
    Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation.
    Gebbia V; Mauceri G; Fallica G; Borsellino N; Tirrito ML; Testa A; Varvara F; Colombo A; Ferrera P
    Oncology; 2002; 63(1):23-30. PubMed ID: 12187067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil).
    Skubitz KM; Skubitz AP
    Anticancer Drugs; 1998 Jan; 9(1):45-50. PubMed ID: 9491791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer.
    Escobar PF; Markman M; Zanotti K; Webster K; Belinson J
    J Cancer Res Clin Oncol; 2003 Nov; 129(11):651-4. PubMed ID: 14505047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.